Zevia PBC (ZVIA) Competitors

vTv Therapeutics (NASDAQ:VTVT) and Zevia PBC (NYSE:ZVIA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Do analysts rate VTVT or ZVIA?

Zevia PBC has a consensus price target of $3.21, suggesting a potential upside of 248.01%. Given vTv Therapeutics' higher possible upside, analysts clearly believe Zevia PBC is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Zevia PBC	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor VTVT or ZVIA?

In the previous week, Zevia PBC had 19 more articles in the media than vTv Therapeutics. MarketBeat recorded 24 mentions for Zevia PBC and 5 mentions for vTv Therapeutics. Zevia PBC's average media sentiment score of 0.65 beat vTv Therapeutics' score of -0.11 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevia PBC	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of VTVT or ZVIA?

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 53.2% of Zevia PBC shares are owned by institutional investors. 1.7% of vTv Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Zevia PBC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has better valuation & earnings, VTVT or ZVIA?

vTv Therapeutics has higher earnings, but lower revenue than Zevia PBC. vTv Therapeutics is trading at a lower price-to-earnings ratio than Zevia PBC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$2.02M	38.59	-$20.25M	-$8.84	-2.93
Zevia PBC	$166.42M	0.40	-$21.49M	-$0.48	-1.92

Is VTVT or ZVIA more profitable?

vTv Therapeutics has a net margin of 0.00% compared to vTv Therapeutics' net margin of -15.58%. Zevia PBC's return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	N/A	-80.41%
Zevia PBC	-15.58%	-37.98%	-24.74%

Which has more risk and volatility, VTVT or ZVIA?

vTv Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Zevia PBC has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Does the MarketBeat Community favor VTVT or ZVIA?

vTv Therapeutics received 336 more outperform votes than Zevia PBC when rated by MarketBeat users. Likewise, 57.83% of users gave vTv Therapeutics an outperform vote while only 31.91% of users gave Zevia PBC an outperform vote.

Company	Underperform	Outperform
vTv Therapeutics	Outperform Votes 351 57.83%	Underperform Votes 256 42.17%
Zevia PBC	Outperform Votes 15 31.91%	Underperform Votes 32 68.09%

Summary

Zevia PBC beats vTv Therapeutics on 10 of the 17 factors compared between the two stocks.